JCI:艾滋病研究突破:团队研发精准方法,让HIV无处可逃!

2017-12-22 Lily 来宝网

杜克大学人类疫苗研究所的研究人员领导了一个更准确的方法来衡量在人群中艾滋病毒感染的发生率,这将有助于改善全世界艾滋病的研究和预防战略。

团队开发了更准确的工具来跟踪新的HIV感染】杜克大学人类疫苗研究所的研究人员领导了一个更准确的方法来衡量在人群中艾滋病毒感染的发生率,这将有助于改善全世界艾滋病的研究和预防战略。

新方法更准确地确定了新的与长期感染,确定在何处目标公共卫生措施和研究的重要区别,以及评价干预措施是否成功减少艾滋病毒传播。

研究人员表示:“最近艾滋病的治疗取得了很大的进步,包括治疗和预防HIV感染的有效抗逆转录病毒药物,已经从根本上改变了艾滋病毒领域的景观。”这项研究于12月21日在《JCI》杂志上发表。

在报告中,研究人员指出:"为帮助确定最有效的预防战略,迫切需要改进从已有感染中分类新感染的方法。”研究人员们致力于开发一种方法来衡量艾滋病毒的发病率,同时考虑到目前流行的独特特征,还能利用最新的见解,了解病毒和身体在感染的早期阶段以及如何相互作用。结果是鉴定天然存在的抗体生物标记的新组合的测定,得到了可使用的4个生物标记的有希望的集合。

新的测定更准确。“更准确的HIV发病率测试可以大大降低研究人员的成本,因为他们需要更小的样本量来参加研究。”此外,从公共卫生的角度来看,更准确的艾滋病毒发病率测试将有助于查明近期感染的热点,因此,预防工作可以更好地针对发生疫情的地方。

原始出处:

James J. Knox, Marcus Buggert, Lela Kardava, et al. T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response. Citation Information: JCI Insight. 2017;2(8):e92943. doi:10.1172/jci.insight.92943.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1811136, encodeId=c2ee18111368f, content=<a href='/topic/show?id=67868683032' target=_blank style='color:#2F92EE;'>#艾滋病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86830, encryptionId=67868683032, topicName=艾滋病研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Wed Mar 28 07:24:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982095, encodeId=8ca01982095c9, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed May 16 19:24:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300100, encodeId=d8b41300100b7, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Dec 24 02:24:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403269, encodeId=f4f414032696a, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Dec 24 02:24:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083797, encodeId=4ee62083e97ce, content=<a href='/topic/show?id=285be342772' target=_blank style='color:#2F92EE;'>#研究突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73427, encryptionId=285be342772, topicName=研究突破)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Jan 03 16:24:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271526, encodeId=eea62e152631, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Fri Dec 22 12:26:50 CST 2017, time=2017-12-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1811136, encodeId=c2ee18111368f, content=<a href='/topic/show?id=67868683032' target=_blank style='color:#2F92EE;'>#艾滋病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86830, encryptionId=67868683032, topicName=艾滋病研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Wed Mar 28 07:24:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982095, encodeId=8ca01982095c9, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed May 16 19:24:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300100, encodeId=d8b41300100b7, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Dec 24 02:24:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403269, encodeId=f4f414032696a, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Dec 24 02:24:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083797, encodeId=4ee62083e97ce, content=<a href='/topic/show?id=285be342772' target=_blank style='color:#2F92EE;'>#研究突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73427, encryptionId=285be342772, topicName=研究突破)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Jan 03 16:24:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271526, encodeId=eea62e152631, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Fri Dec 22 12:26:50 CST 2017, time=2017-12-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1811136, encodeId=c2ee18111368f, content=<a href='/topic/show?id=67868683032' target=_blank style='color:#2F92EE;'>#艾滋病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86830, encryptionId=67868683032, topicName=艾滋病研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Wed Mar 28 07:24:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982095, encodeId=8ca01982095c9, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed May 16 19:24:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300100, encodeId=d8b41300100b7, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Dec 24 02:24:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403269, encodeId=f4f414032696a, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Dec 24 02:24:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083797, encodeId=4ee62083e97ce, content=<a href='/topic/show?id=285be342772' target=_blank style='color:#2F92EE;'>#研究突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73427, encryptionId=285be342772, topicName=研究突破)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Jan 03 16:24:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271526, encodeId=eea62e152631, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Fri Dec 22 12:26:50 CST 2017, time=2017-12-22, status=1, ipAttribution=)]
    2017-12-24 lqvr
  4. [GetPortalCommentsPageByObjectIdResponse(id=1811136, encodeId=c2ee18111368f, content=<a href='/topic/show?id=67868683032' target=_blank style='color:#2F92EE;'>#艾滋病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86830, encryptionId=67868683032, topicName=艾滋病研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Wed Mar 28 07:24:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982095, encodeId=8ca01982095c9, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed May 16 19:24:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300100, encodeId=d8b41300100b7, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Dec 24 02:24:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403269, encodeId=f4f414032696a, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Dec 24 02:24:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083797, encodeId=4ee62083e97ce, content=<a href='/topic/show?id=285be342772' target=_blank style='color:#2F92EE;'>#研究突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73427, encryptionId=285be342772, topicName=研究突破)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Jan 03 16:24:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271526, encodeId=eea62e152631, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Fri Dec 22 12:26:50 CST 2017, time=2017-12-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1811136, encodeId=c2ee18111368f, content=<a href='/topic/show?id=67868683032' target=_blank style='color:#2F92EE;'>#艾滋病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86830, encryptionId=67868683032, topicName=艾滋病研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Wed Mar 28 07:24:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982095, encodeId=8ca01982095c9, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed May 16 19:24:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300100, encodeId=d8b41300100b7, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Dec 24 02:24:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403269, encodeId=f4f414032696a, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Dec 24 02:24:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083797, encodeId=4ee62083e97ce, content=<a href='/topic/show?id=285be342772' target=_blank style='color:#2F92EE;'>#研究突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73427, encryptionId=285be342772, topicName=研究突破)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Jan 03 16:24:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271526, encodeId=eea62e152631, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Fri Dec 22 12:26:50 CST 2017, time=2017-12-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1811136, encodeId=c2ee18111368f, content=<a href='/topic/show?id=67868683032' target=_blank style='color:#2F92EE;'>#艾滋病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86830, encryptionId=67868683032, topicName=艾滋病研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Wed Mar 28 07:24:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982095, encodeId=8ca01982095c9, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed May 16 19:24:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300100, encodeId=d8b41300100b7, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Dec 24 02:24:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403269, encodeId=f4f414032696a, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Dec 24 02:24:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083797, encodeId=4ee62083e97ce, content=<a href='/topic/show?id=285be342772' target=_blank style='color:#2F92EE;'>#研究突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73427, encryptionId=285be342772, topicName=研究突破)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Jan 03 16:24:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271526, encodeId=eea62e152631, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Fri Dec 22 12:26:50 CST 2017, time=2017-12-22, status=1, ipAttribution=)]
    2017-12-22 衣带渐宽

    学习

    0

相关资讯

Nat Commun:科学家发现抑制了艾滋病毒感染的能力

用显微镜观察,这种病毒就像菠萝一样。但是,艾滋病毒是导致艾滋病的病毒,到目前为止,它已经夺去了3500多万人的生命。

七年艾滋“阴影”下的损失 谁来买单?

2008年12月,对家住四川成都金牛区的钟啸伟来说是可怕的一天。在这一天,钟啸伟拿着医院的检验报告单,被告知感染了艾滋病。但在7年里一直没有症状的他到华西医院再次做了抽血检查,结果却显示是阴性。他说,7年来,自己唯一活着的目的就是等死。谁该为这场历经7年的痛苦负责任?钟啸伟告诉记者,自己原本打算2009年“五一”结婚,为了对双方负责任,他和女友决定在成都市疾控中心做一次艾滋病检查。“血样样品是我亲

艾滋病感染科医生首次进驻台北社区诊所

据港媒报道,12月1日是世界艾滋病日,台湾卫生福利部门当天宣布,2018年起预计新增4家艾滋病指定医院、13家艾滋病指定药局,并在台北试办首家有艾滋病指定医院感染科医生进驻的社区诊所。根据台湾疾病管制部门统计,台湾累计有36000多名艾滋病感染者,其中25岁到34岁的感染者占了43%。该部门负责人罗一钧指出,台湾约有6%至10%感染者未持续就医,可能导致病毒控制不佳,引起后续并发重症、死亡和传播他

武汉现23起艾滋病职业暴露 医护人员达15人

艾滋病职业暴露是指医务人员、防疫人员、公安等在诊治艾滋病病毒感染者及相关工作中,意外被含有艾滋病病毒的血液、体液等污染了黏膜或破损的皮肤,或被含有病毒的针头刺破皮肤。截至今天,武汉市今年一共发生了23起艾滋病职业暴露事件,其中一半以上为医护人员。所幸经过及时的药物阻断治疗,无一人感染艾滋病。

Lund Uni:埃塞俄比亚成为世界艾滋病很大“重灾区”,与这个原因分不开!

在世界许多地方,围绕艾滋病毒的社会污名仍然很强烈。埃塞俄比亚的艾滋病毒感染儿童由于受到根深蒂固的偏见,面临接受治疗不足或根本没有治疗的高风险。在非常小的孩子身上发现了最大的风险,他们没有立即得到适当的治疗。 在世界许多地方,围绕艾滋病毒的社会污名仍然很强烈。埃塞俄比亚的艾滋病毒感染儿童由于受到根深蒂固的偏见,面临接受治疗不足或根本没有治疗的高风险。在非常小的孩子身上发现了最大的风险,他们没有立即

J Infect Dis:以毒攻毒”HIV治疗出现新的方法,有助于治愈HIV

尽管渥太华的研究人员因其抗癌病毒的研究而闻名,但有一个研究小组将这些病毒应用于一个新的目标:艾滋病病毒。